Paul Klingenstein founded Aberdare in 1999.
His current focus is on those technologies which drive transformational efficiencies in care, leading Aberdare commitments in areas such as personalized medicine (Clovis Oncology), biosensor systems (mc10), molecular diagnostics (Aviir), and integrated patient data systems (Elation EMR). Earlier at Aberdare, he helped establish the firm as a leading healthcare venture investor through commitments to more traditional technologies such as drug discovery and development (Pharmion, Ironwood, Anacor) and highly engineered interventional devices (Ablation Frontiers, Nevro).
Prior to founding Aberdare, Paul was an advisor to the Rockefeller Foundation, where he helped launch the first public private partnership, directed at finding a broadly effective vaccine for HIV.
At Accel Partners (1986 – 1997) he led a highly successful healthcare effort. He invested in and served on the board of Aviron, Isis Pharmaceuticals, Viagene, Neurex, Glycomed, US Behavioral Health, Amerigroup, Xomed Surgical Products, and others.
After working as a field biologist and Outward Bound instructor in Africa, he began his investment career at Warburg Pincus in New York. In the early 1980s, he had the opportunity to be a participant in the last wave of systemic transformation, through his involvement in first generation biotechnology (Synergen, Vestar) and managed care (U.S. Healthcare).
Paul serves as Board Chair of the International AIDS Vaccine Initiative and as a member of the Board of the MacArthur Foundation. He is a former trustee of the Taft School and the Marin Country Day School. He received his AB from Harvard College and his MBA from the Stanford Graduate School of Business.